Collaborative virtual reality improves walking

Trial ID
NCT07523425
Official Title
COMPARATIVE EFFECTIVENESS of COLLABORATIVE VIRTUAL ENVIRONMENT and NON-IMMERSIVE VIRTUAL REALITY in the REHABILITATION of PATIENTS With PARKINSON'S DISEASE
Goal
Collaborative virtual reality improves walking
Phase
NA
Status
RECRUITING
Sponsor
Superior University
Study Type
INTERVENTIONAL
Enrollment
60 participants
Conditions
Parkinson Desease
Interventions
Collaborative Virtual Environment, Non-Immersive Virtual Reality (NIVR)

Plain-Language Summary

Goal: to see whether a collaborative virtual environment where people work together in the same virtual space improves balance, gait, and everyday motor function more than standard non-immersive, screen-based virtual reality. Approach: participants do guided, task-based exercises using sensors or a screen, the collaborative setup adds social interaction and real-time visual and auditory feedback to boost motor learning, while the non-immersive option gives individual practice; both are rehab tools meant to complement, not replace, stable Parkinson's medications. Eligibility: adults 45 to 80 with idiopathic Parkinson's at Hoehn and Yahr stages I to III, on stable conventional treatment, with no severe cognitive impairment (MMSE ≥ 24) and able to tolerate virtual sessions, excluding people with severe sensory problems, epilepsy, or other conditions that block participation.

Locations

  • Punjab Institute of Neurosciences Lahore, Lahore, Punjab Province, Pakistan

Frequently Asked Questions

What is this trial testing?
This trial is studying Collaborative Virtual Environment. Goal: to see whether a collaborative virtual environment where people work together in the same virtual space improves balance, gait, and everyday motor function more than standard non-immersive, screen-based virtual reality. Approach: participants do guided, task-based exercises using sensors or a screen, the collaborative setup adds social interaction and real-time visual and auditory feedback to boost motor learning, while the non-immersive option gives individual practice; both are rehab tools meant to complement, not replace, stable Parkinson's medications. Eligibility: adults 45 to 80 with idiopathic Parkinson's at Hoehn and Yahr stages I to III, on stable conventional treatment, with no severe cognitive impairment (MMSE ≥ 24) and able to tolerate virtual sessions, excluding people with severe sensory problems, epilepsy, or other conditions that block participation.
Who can participate?
Participants must be between 45 Years and 80 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 1 year and 4 months.

View on ClinicalTrials.gov